title: Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure.
authors.forename: Thomas
authors.initials: T
authors.lastname: Prébet
authors.forename: Steven D
authors.initials: SD
authors.lastname: Gore
authors.forename: Sylvain
authors.initials: S
authors.lastname: Thépot
authors.forename: Benjamin
authors.initials: B
authors.lastname: Esterni
authors.forename: Bruno
authors.initials: B
authors.lastname: Quesnel
authors.forename: Odile
authors.initials: O
authors.lastname: Beyne Rauzy
authors.forename: François
authors.initials: F
authors.lastname: Dreyfus
authors.forename: Claude
authors.initials: C
authors.lastname: Gardin
authors.forename: Pierre
authors.initials: P
authors.lastname: Fenaux
authors.forename: Norbert
authors.initials: N
authors.lastname: Vey
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D001374:Azacitidine / Q000031:analogs & derivatives*; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000401:mortality*; D008297:Male; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000401:mortality*; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine